

PATENT
Customer No. 22,852
Attorney Docket No. 09605.0012

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Emma TERRICABRAS BELART et al.) Group Art Unit: Not yet assigned
Application No.: Not yet assigned) Examiner: Not yet assigned
Filed: Herewith)
For: 4-AMINOTHIENO[2,3-d]PYRIMIDINE-) Confirmation No.: Not yet assigned
6-CARBONITRILE DERIVATIVES AS)
PDE7 INHIBITORS)

being a U.S. National Phase of PCT/EP2004/000584

MAIL STOP: PCT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage in an international application.

Copies of the listed foreign and non-patent literature documents are attached.

The following applies to the attached non-English document:

WO 98/17668—Applicants are submitting herewith an esp@cenet abstract for this document. Applicants are also listing U.S. Patent No. 6,130,223 in the attached form PTO /SB/08, which is believed to be related to WO 98/17668.

Applicants respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material

or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: 

Anthony C. Tridico
Reg. No. 45,958

Dated: July 21, 2005

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Application Number</i>	<i>10/542940</i>
				<i>Filing Date</i>	Hereinwith
				<i>First Named Inventor</i>	Emma BELART-TERRICABRAS et al.
				<i>Art Unit</i>	
				<i>Examiner Name</i>	
Sheet	1	of	1	<i>Attorney Docket Number</i>	09605.0012

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		EP 0 728 759	08/28/1996	Ono Pharmaceutical Co.		
		WO98/17668	04/30/1998	Merck		Abstract

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		<u>esp@cenet</u> Abstract for WO98/17668, published on April 30, 1998	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.